PO.CL09.03 · 临床研究

一种将体细胞拷贝数变异纳入多灶性非小细胞肺癌比较基因组分析的贝叶斯框架

A Bayesian framework for evaluating somatic copy number variants into comparative genomic analysis of multifocal non-small cell lung cancer

海报缩略图:一种将体细胞拷贝数变异纳入多灶性非小细胞肺癌比较基因组分析的贝叶斯框架
编号 5423 展板 13 时间 4/21 09:00–12:00 区域 Section 49 主讲 Claire Teigen
分会场 Retrospective Observational Studies
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Claire Teigen, Ying-Chun Lo, Sounak Gupta, Stephanie Smoley, Beth Pitel, Hussam Al Kateb, Gopi Sivasankaran, Benjamin Kipp, Ande Rumilla, Gang Zheng, Kevin Halling, Katherine Geiersbach

Mayo Clinic, Rochester, MN

摘要 Abstract

中文摘要
引言:多灶性非小细胞肺癌(NSCLC)的临床分期可通过对不同肿瘤结节的比较基因组分析来促进,但全基因组拷贝数分析在此目的中的作用尚不确定。 方法:我们分析了一个回顾性队列中34例具有>1个肺癌结节的患者的单核苷酸变异(SNVs)、基因融合、小拷贝数变异(基因扩增和纯合缺失)(sCNVs)和大规模拷贝数变异(lCNVs),这些患者在先前经过验证的仅肿瘤515基因下一代测序(NGS)panel(MayoComplete实体瘤Panel)上进行了检测。对于共享SNVs<2个的患者,制定了一种贝叶斯方法来计算同一患者不同肿瘤结节中发生共享事件与独立事件的概率。特定lCNVs在NSCLC中的患病率来自一个由同一panel检测的100例NSCLC同类患者的独立数据集,而SNVs、融合和sCNVs在NSCLC中的患病率来自公开可用数据。不同肿瘤结节独有的改变和疑似胚系改变被排除于贝叶斯分析之外。 结果:34例患者共有54次比较。11例患者(32.4%)具有>=2个共享SNVs,同时每例患者中还识别出一个或多个共享lCNVs。8例患者(23.5%)没有共享的SNVs、基因融合、sCNVs或lCNVs。对其余15例(44.1%)具有至少一个共享改变(SNVs、sCNVs和lCNVs)的患者使用贝叶斯方法,克隆相关性的概率范围从共享整臂或整条染色体lCNV的73%到具有两个或多个共享改变(包括多个或复杂lCNVs和SNVs)肿瘤的>99%。整条染色体或整臂lCNVs有时在具有不同驱动SNVs的肿瘤结节之间共享。 结论:将lCNVs纳入比较基因组分析,在一部分多灶性NSCLC中提供了克隆相关性的额外证据。然而,用于识别lCNVs的生物信息学流程的差异、对全基因组拷贝数分析不精确性的担忧,以及关于lCNVs与癌变之间时间关系(包括可能与"区域癌化"相关的体细胞事件)的不确定性,为将lCNVs整合到石蜡包埋组织切片仅肿瘤NGS的标准临床工作流程的比较基因组分析中带来了挑战。我们的简化方法减轻了将lCNVs纳入克隆性判定所引入的部分不确定性。
查看英文原文 English abstract
Introduction: Clinical staging of multifocal non-small cell lung cancer (NSCLC) is facilitated by comparative genomic analysis of separate tumor nodules, but the role of genome-wide copy number profiling for this purpose is uncertain. Methods: We analyzed single nucleotide variants (SNVs), gene fusions, small copy number variants (gene amplifications and homozygous deletions) (sCNVs), and large-scale copy number variants (lCNVs) in a retrospective cohort of 34 patients with >1 lung cancer nodule tested on a previously validated tumor-only 515-gene next generation sequencing (NGS) panel (MayoComplete Solid Tumor Panel). For patients with <2 shared SNVs, a Bayesian approach was formulated to calculate the probability of shared versus independent events occurring in different tumor nodules in the same patient. The prevalence of specific lCNVs in NSCLC was derived from an independent dataset of 100 NSCLC peers tested by the same panel, and the prevalence of SNVs, fusions, and sCNVs in NSCLC was derived from publicly available data. Alterations unique to different tumor nodules and suspected germline alterations were excluded from the Bayesian analysis. Results: There were 54 total comparisons for 34 patients. Eleven of the patients (32.4%) had >=2 shared SNVs along with one or more shared lCNVs also identified in each patient. Eight patients (23.5%) had no shared SNVs, gene fusions, sCNVs, or lCNVs. Using the Bayesian approach for the remaining fifteen (44.1%) patients with at least one shared alteration (SNVs, sCNVs, and lCNVs), the probability of clonal relatedness ranged from 73% for a shared whole arm or whole chromosome lCNV to >99% for tumors with two or more shared alterations including multiple or complex lCNVs and SNVs. Whole chromosome or whole arm lCNVs were sometimes shared between tumor nodules with different driver SNVs. Conclusions: Incorporating lCNVs into comparative genomic analysis provides additional evidence of clonal relatedness in a subset of multifocal NSCLCs. However, differences in bioinformatics pipelines for calling lCNVs, concerns over the imprecision of genome-wide copy number profiling, and uncertainty regarding the temporal relationship between lCNVs and carcinogenesis (including somatic events possibly related to “field cancerization”) create challenges for integrating lCNVs into comparative genomic analysis with standard clinical workflows for tumor-only NGS on paraffin embedded tissue sections. Our simplified approach mitigates some of the uncertainty introduced by incorporating lCNVs into clonality determination.
利益披露 Disclosure
C. Teigen, None. Y. Lo, Biocartis Other, Consultation. Bio2Market Other, Consultation. Boehringer Ingelheim Other, Consultation. BioCode Other, Consultation. S. Gupta, None.. S. Smoley, None.. B. Pitel, None.. H. Al Kateb, None.. G. Sivasankaran, None.. B. Kipp, None.. A. Rumilla, None.. G. Zheng, None.. K. Halling, None.. K. Geiersbach, None.

← 返回 AACR 2026 检索